HIF-1α in heart: Protective mechanisms

Joseph C. Wu, Ping Chen, Ying Li, Chris L Ardell, Tatyana Der, Ralph V. Shohet, Minghua Chen, Gary L. WrightAmerican 2013 · DOI

TL;DR

This study investigates the protective role of Hypoxia-Inducible Factor-1α (HIF-1α) in the heart against ischemic injury. They found that while HIF-1α does enhance compensatory mechanisms like glycogen storage and glycolysis, these adaptations aren't strictly necessary for its cardioprotective effects, suggesting alternative, mitochondrion-focused protective pathways.

What Problem Does This Paper Address?

The heart is highly susceptible to damage from ischemia (lack of blood flow), a common feature of heart disease. Hypoxia-Inducible Factor-1α (HIF-1α) is a well-known transcription factor that orchestrates cellular responses to low oxygen conditions. While its role in other tissues, particularly cancer, is extensively studied, its specific protective mechanisms in the heart against ischemic injury are less clear. Previous research hinted at HIF-1α's involvement in cardioprotection, but the precise molecular pathways responsible remained elusive. This paper aims to elucidate whether HIF-1α is sufficient to protect the heart from ischemia-reperfusion injury and to explore the underlying mechanisms.

Methods

The researchers utilized a sophisticated mouse model engineered to express a stabilized, doxycycline (Dox)-regulated HIF-1α transgene specifically in cardiac myocytes. This allowed them to control the induction of HIF-1α expression. They compared hearts from wild-type (WT) mice with those from transgenic mice that were either not induced (Non-I) or induced to express HIF-1α for 2 days (2D) or 6 days (6D) by withholding doxycycline.

Key experimental techniques included:

  • Langendorff Perfusion: Isolated hearts were perfused to simulate physiological conditions and subjected to controlled periods of ischemia followed by reperfusion.
  • Functional Assessment: Left ventricular developed pressure (LVDP) was measured to assess heart function before, during, and after the ischemic insult.
  • Tissue Viability Assay: Triphenyltetrazolium chloride (TTC) staining was used to quantify the extent of viable heart tissue after the ischemic event.
  • Biochemical Assays: Glycogen content, lactic acid release, ATP and ADP levels were measured to assess metabolic changes.
  • Western Blotting: Protein levels of HIF-1α and glycogen synthase were determined.
  • Mitochondrial Membrane Potential Measurement: Isolated cardiomyocytes were subjected to anoxia or metabolic inhibition (using cyanide and 2-deoxyglucose) to assess mitochondrial function using TMRM fluorescence.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • HIF-1α is Sufficient for Cardioprotection: The study demonstrates that inducing HIF-1α expression in cardiac myocytes is enough to confer significant protection against ischemic-reperfusion injury, even at low levels of expression (as seen in Non-I hearts).
  • Glycolysis is Not the Sole Protector: While HIF-1α does increase glycogen stores and glycolytic flux during ischemia, the Non-I hearts, which showed minimal increases in these parameters, were protected to the same extent as the more highly induced hearts. This suggests that these metabolic adaptations are not the primary drivers of protection.
  • Mitochondrial Integrity is Key: The most striking finding is that HIF-1α-expressing cardiomyocytes maintain mitochondrial membrane potential significantly better than WT cells, even when both oxidative phosphorylation and glycolysis are blocked. This points to a direct protective effect on mitochondria as a crucial mechanism.
  • "Hibernating Myocardium" Link: The observed increase in glycogen synthase and glycogen accumulation in HIF-1α-expressing hearts aligns with the characteristics of hibernating myocardium, suggesting HIF-1α might play a role in this adaptive state.

Key Results

  • Functional Recovery: Recovery of left ventricular developed pressure (LVDP) after 30 minutes of ischemia was significantly higher in Non-I (67%), 2D-induced (64%), and 6D-induced (62%) HIF-1α hearts compared to WT hearts (14%).
  • Tissue Viability: Tissue viability correlated with functional recovery, with HIF-1α-expressing hearts showing significantly less damage.
  • Metabolic Changes: 6D-induced HIF hearts exhibited increased preischemic glycogen reserves and higher lactic acid release during ischemia. They also maintained higher ATP levels during ischemia compared to WT and Non-I hearts.
  • Mitochondrial Protection: In isolated cardiomyocytes, HIF-1α expression protected mitochondrial membrane potential during anoxia and metabolic inhibition. This protection was evident even when glycolysis was blocked.

Limitations and Future Work

  • "Leakage" in Non-Induced Hearts: The study acknowledges that Non-I hearts had some baseline HIF-1α expression due to promoter "leakiness," which might contribute to their protection. However, the protection was still significant and comparable to induced hearts, highlighting the sensitivity of the system.
  • Unexplained Absence of Reduced Oxidative Phosphorylation: The authors note that their findings of reduced oxidative phosphorylation and ATP turnover, observed in other models of HIF-1α activation, were not detected in their 6D-induced hearts. This discrepancy warrants further investigation.
  • Future Directions: The authors suggest that further studies are needed to quantitatively measure the flux through fumarate respiratory pathways, which HIF-1α is known to induce, and to fully elucidate the mechanisms by which HIF-1α preserves mitochondrial function during ischemia. They also plan to explore the role of HIF-1α in the hibernating myocardium phenotype.

Summary updated

Abstract

Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that directs many of the cellular responses to hypoxia. In these studies, we have used a mouse model containing a cardiac-specific, oxygen-stabilized, doxycycline (Dox)-off regulated HIF-1α transgene to probe the role of HIF-1α in cardioprotection. Hearts used in these studies were derived from wild-type (WT), noninduced (Non-I), and 2 day (2D) and 6 day (6D) Dox-deprived mice. Whereas HIF-1α protein is undetectable in WT mice, it is present in heart tissue of "noninduced" transgenic mice, presumably because of leakiness of the promoter construct. In mice denied Dox for 2 or 6 days, HIF-1α is overexpressed to a much greater extent than Non-I or WT animals, as expected. WT and HIF-1α-expressing hearts (Non-I, 2D and 6D induced) were subjected to 30 min of ischemia, and functional recovery was measured upon reperfusion. Recovery of preischemic left ventricular developed pressure was 14% for WT, 67% for Non-I hearts, 64% for 2D-induced, and 62% for 6D-induced hearts. 6D-induced HIF hearts have increased preischemic glycogen reserves, higher glycogen synthase protein levels, and significantly higher lactic acid release during ischemia. 6D-induced HIF hearts were also better able to maintain ATP levels during ischemia compared with WT and Non-I hearts. Interestingly, Non-I hearts showed no significant increase in glycogen reserves, glycolytic flux, or greater ATP preservation during ischemia and yet were protected to a similar extent as the 6D-induced hearts. Finally, the mitochondrial membrane potential of isolated adult myocytes was monitored during anoxia or treatments with cyanide and 2-deoxyglucose. HIF-1α expression was shown to protect mitochondrial polarization during both stress treatments. Taken together these data indicate that, while HIF-1α expression in heart does induce increases in compensatory glycolytic capacity, these changes are not necessarily required for cardioprotection, at least in this model of ischemic stress.
BibTeX
@inproceedings{wu2013hif,
  author = {Joseph C. Wu and Ping Chen and Ying Li and Chris L Ardell and Tatyana Der and Ralph V. Shohet and Minghua Chen and Gary L. Wright},
  title = {{HIF-1α in heart: Protective mechanisms}},
  booktitle = {American},
  year = {2013},
  doi = {10.1152/ajpheart.00140.2013},
}
Figure